Tobacco control efforts in the U.S. have predominantly been a state, local, and increasingly tribal endeavor with landmark federal reports and legislation spurring or guiding local actions. When I started in tobacco control at the local level in 2006, the CDC’s Best Practices for Comprehensive Tobacco Control Programs was our roadmap. It focused our efforts […]
On December 11, 2013, the Food Drug Administration (FDA) issued guidelines aimed at phasing out the use of antibiotics that are critical to human health in food-producing animals, including penicillin, azithromycin and tetracycline. Aside from treating infections in animals, livestock producers have been using antibiotics to induce growth in an animal and maximize feed. The […]
Posted in FDA ; Tagged: animal, Animal Health Institute, Antibiotic resistance, Antibiotics, Bayer, Center for Veterinary Medicine, drug, drug companies, drug resistance, drugs, Elanco, infectious diseases, Johns Hopkins, Johns Hopkins Center for a Livable Future, Merck, Novartis, Pharmaceuticals, public health, Sanofi, Zoetis.
In a decision that could save U.S. consumers and taxpayers billions of dollars a year, the Supreme Court ruled Monday that “pay-for-delay,” also known as “reverse payment” settlements, between name-brand and generics pharmaceutical companies are subject to antitrust laws. The seeds of the controversy were planted in 1984 with the passage of the Hatch-Waxman […]
Signup for our mailing list and stay up to date on the latest happenings at The O’Neill Institute
Or sign up for our RSS Feed
The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.